GTBP.US GT Biopharma Inc

Healthcare Biotechnology USA Stocks
3.72 USD
Close of Nov 15, 2026
3.60 23.60
Market cap
USD 7.67M
P/E
-
P/B
1.88x
ROE
-411.9%
Dividend yield
2.99%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is GTBP.US undervalued?

Graham number

The Graham number of GT Biopharma Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GT Biopharma Inc fundamental analysis

No fundamental analysis for GT Biopharma Inc yet.

GT Biopharma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GT Biopharma Inc

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface o…

Full company profile